Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210315992ADJUVANT EFFECT OF THE TLR1/2 AGONIST DIPROVOCIM SYNERGIZES WITH CHECKPOINT-INHIBITING ANTIBODIES TO ELIMINATE DISEASE
US 14.10.2021
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
Appl.No 17265333 Applicant The Board of Regents of the University of Texas System Inventor Bruce Beutler

A potent human and mouse Toll-like receptor (TLR)1/TLR2 agonist was identified and optimized, Diprovocim, which exhibited an EC50 of 110 pM in human THP-1 cells and 1.3 nM in primary mouse peritoneal macrophages. In mice, Diprovocim-adjuvanted ovalbumin immunization promoted antigen-specific humoral and CTL responses, and synergized with anti-PD-L1 treatment to inhibit tumor growth, generating long-term anti-tumor memory, curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA. Diprovocim induced greater frequencies of tumor infiltrating leukocytes than alum, of which CD8 T cells were necessary for the antitumor effect of immunization plus anti-PD-L1 treatment.

2.WO/2021/204878USE OF CDON INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
WO 14.10.2021
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No PCT/EP2021/059066 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor RENAULT, Marie-Ange
Endothelial dysfunction is a hallmark of peripheral arterial disease which is defined as vascular occlusion below the level of the inguinal ligament, and which is one of the most severe complications of diabetes and inflammatory conditions such as sepsis. Evidences accumulated within the past decades, identified Hedgehog (Hh) signaling as a new regulator of micro-vessel integrity. The purpose of the inventors was to investigate whether Hh co-receptors Gas1 and Cdon may be used as therapeutic targets to modulate Dhh signaling in ECs. The inventors demonstrated that both Gas1 and Cdon are expressed in adult ECs and relied on either siRNAs or EC specific conditional KO mice to investigate their role. They found that Gas1 deficiency mainly photocopies Dhh deficiency especially by inducing VCAM-1 and ICAM-1 overexpression while Cdon deficiency has opposite effects by promoting endothelial junction integrity. At a molecular level, Cdon prevents Dhh binding to Ptch1 and thus acts a decoy receptor for Dhh, while Gas1 promotes Dhh binding to Smo and as a result potentiates Dhh effects. Since Cdon is overexpressed in ECs treated by inflammatory cytokines including TNFα and Il1β, the inventors then tested whether Cdon inhibition would promote endothelium integrity in acute inflammatory conditions and found that both fibrinogen and IgG extravasation were decreased in association with an increased Cdh5 expression in the brain cortex of EC specific Cdon KO mice administered locally with Il1β. Altogether these results demonstrate that Cdon is a negative regulator and justify that Cdon blocking molecules may be used to promote endothelium integrity at least in inflammatory conditions.
3.WO/2021/204998NATURAL ANTIBODIES IN PROPHYLAXIS AND THERAPY
WO 14.10.2021
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
Appl.No PCT/EP2021/059294 Applicant HEIDELBERG IMMUNOTHERAPEUTICS GMBH Inventor ÜBELHART, Rudolf
Described is a human or humanized natural IgM and/or IgA antibody recognizing oxidized phospholipids and/or oxidation-specific epitopes for use in a method of treating or preventing a disorder or a disease associated with/related to/caused by a natural IgM/lgA antibody deficiency (NAD) in a subject. Moreover, described is a vaccine comprising a compound that induces the generation of natural IgM and/or IgA antibodies for use in a method of reducing or preventing the clinical signs or disease associated with/related to/caused by natural IgM/lgA antibody deficiency (NAD) in a subject, wherein said vaccine comprises a pharmaceutically acceptable carrier or excipient. Further, described is such a vaccine for use in a method of reducing or preventing the clinical signs or disease associated with/related to/caused by natural IgM/lgA antibody deficiency (NAD) in a subject, wherein said compound induces human natural IgM and/or IgA antibody recognizing oxidized phospholipids and/or oxidation-specific epitopes.
4.WO/2021/206078MEDICINE FOR KILLING TUMOR CELLS
WO 14.10.2021
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/JP2021/014588 Applicant PHOTOQ3 INC. Inventor TODA Naoko
The present invention addresses the problem of providing a medicine for killing tumor cells, said medicine having few side effects. According to the present invention, provided is a medicine, said medicine comprising a conjugate of a substance capable of binding to a target substance on the surface of tumor cells and a cytotoxin, and a photosensitive dye, and being for killing tumor cells in which the target substance is expressed in a small amount.
5.20210315989METHODS TO PREPARE NASOPHARYNGEAL AND ORAL MATERIAL FOR ORAL INOCULATION OF COVID-19
US 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17223920 Applicant Steven Mark Hayden Inventor Steven Mark Hayden

The instant disclosure relates generally to oral inoculation and specifically to methods to prepare nasopharyngeal and oral material for oral inoculation of COVID-19. Severe acute respiratory syndrome coronavirus 2 (“SARS-CoV-2”) viral particles are collected from at least one of a nasopharyngeal specimen and an oral specimen each derived from a patient infected with SARS-CoV-2 or a SARS-CoV-2 variant. Mammalian cells (e.g., Vero-E6 and/or Vero-CCL81 cells) are infected with the SARS-CoV-2 viral particles to produce infected mammalian cells. The infected mammalian cells are cultured to produce a mammalian cell culture. SARS-CoV-2 viral particles are collected from the mammalian cell culture to produce isolated viral particles. The isolated viral particles are frozen to produce a frozen isolate. The frozen isolate is partitioned into a plurality of tablets each having a therapeutically effective amount of the SARS-CoV-2 viral particles. An enteric coating is applied to each tablet.

6.WO/2021/203769USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF DRUGS FOR TREATING ACRAL LENTIGINOUS MELANOMA
WO 14.10.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2021/000069 Applicant JIANGSU HENGRUI MEDICINE CO., LTD. Inventor ZOU, Jianjun
Provided is a use of an anti-PD-1 antibody and apatinib in preparation of drugs for treating acral lentiginous melanoma. The solution has a disease control rate of 72.2% against acral lentiginous melanoma, and has an objective response rate of 22.2%. Also provided is a use of an anti-PD-1 antibody, apatinib, and temozolomide in preparation of drugs for treating melanoma.
7.WO/2021/204204ANTIGEN GENE TRANSFECTION CELL VACCINE AND RELATED IMMUNE CELL
WO 14.10.2021
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No PCT/CN2021/085973 Applicant CHINEO MEDICAL TECHNOLOGY CO., LTD. Inventor GU, Weiyue
Provided are a cell vaccine for an infection by a pathogenic micro-organism and an illness related to the infection, said vaccine can be prepared by means of in vitro transfection of autologous or allogeneic antigen-presenting cells with a pathogenic micro-organism antigen, and as such the antigen-presenting cells loaded with the pathogenic micro-organism antigen serve as a prophylactic or therapeutic vaccine. Further provided are an immune cell, comprising a T cell or an NK cell, which can be activated by the antigen-loaded vaccine of the present invention, or can be directly activated by a pathogenic micro-organism. Further provided is a composition simultaneously including the cell vaccine and immune cells, said composition being used for preventing or treating an infection caused by the pathogenic micro-organism and an illness related thereto.
8.WO/2021/205216TREATMENT OF MOST BOTHERSOME SYMPTOM (MBS) ASSOCIATED WITH MIGRAINE USING ANTI-CGRP ANTIBODIES
WO 14.10.2021
Int.Class C07K 16/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
26against hormones
Appl.No PCT/IB2020/053568 Applicant H. LUNDBECK A/S Inventor CADY, Roger, K.
Methods for treatment of most bothersome symptom (MBS) associated with migraine are provided. Exemplary methods provide improvement in MBS associated with migraine within 1 month of administration og anti-CGRP antibodies of the invention. Also provided are methods for improvement of patient impression of change (PGIC) associated with migraine. Exemplary methods comprise administration of an anti-CGRP antagonistic antibody to a patient in need thereof.
9.WO/2021/205359ANTI-PHF-TAU ANTIBODIES AND USES THEREOF
WO 14.10.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/IB2021/052890 Applicant JANSSEN BIOTECH, INC. Inventor VAN KOLEN, Kristof
Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
10.WO/2021/207249VACCINE PLATFORM FOR THE INDUCTION OF SYSTEMIC IMMUNE RESPONSES
WO 14.10.2021
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2021/026022 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor CHERPES, Thomas L.
Compositions and methods are provided relating to vaccine formulations comprising (i) an agent that specifically binds to CD244; (ii) an effective dose of an antigen; and (iii) an adjuvant, which adjuvant can be, without limitation, an activator of innate-like T cells.